Last reviewed · How we verify
Lactobacillus casei
Lactobacillus casei is a probiotic bacterium that colonizes the gut and modulates the intestinal microbiota and immune system to promote gastrointestinal and systemic health.
Lactobacillus casei is a probiotic bacterium that colonizes the gut and modulates the intestinal microbiota and immune system to promote gastrointestinal and systemic health. Used for Gastrointestinal health maintenance, Antibiotic-associated diarrhea prevention, Immune system support.
At a glance
| Generic name | Lactobacillus casei |
|---|---|
| Sponsor | Hospital Cristo Re |
| Drug class | Probiotic |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Immunology |
| Phase | FDA-approved |
Mechanism of action
L. casei produces lactic acid and bacteriocins that inhibit pathogenic bacteria, strengthens the intestinal barrier function, and stimulates both innate and adaptive immune responses through interaction with gut-associated lymphoid tissue. This leads to improved digestive health, enhanced immune tolerance, and potential reduction of gastrointestinal and systemic infections.
Approved indications
- Gastrointestinal health maintenance
- Antibiotic-associated diarrhea prevention
- Immune system support
Common side effects
- Gastrointestinal disturbance (bloating, gas)
- Mild abdominal discomfort
Key clinical trials
- ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
- Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease (PHASE2)
- A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) (PHASE2)
- S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer (PHASE3)
- A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer (PHASE1, PHASE2)
- Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) (PHASE3)
- A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (PHASE3)
- A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lactobacillus casei CI brief — competitive landscape report
- Lactobacillus casei updates RSS · CI watch RSS
- Hospital Cristo Re portfolio CI